Icahn funds unload stakes in Biogen, Amgen

A few drugmakers might breathe sighs of relief at activist investor Carl Icahn's (photo) latest portfolio update. Icahn's investment vehicles appear to have sold out of Biogen Idec, at which they forced two proxy fights, as well as Amgen and Regeneron Pharmaceuticals. Report